Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard therapies and adverse events leading to therapy discontinuation. A study at The University of Texas MD Anderson Cancer Center revealed new information about how the biomarkers retinoblastoma protein (Rb) and cytoplasmic cyclin E could indicate which patients will respond best to current first-line...
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public...
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new radiation technology aimed at reducing side effects of standard radiation including unwanted radiation to healthy tissue.
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy and radiosurgery option. MD Anderson will develop technologies...
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered...
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated...
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused...
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast...